A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL
As the most common subtype of lymphoma, diffuse large B-cell lymphoma (DLBCL) is an aggressive but potentially curable malignancy. However, patients with early relapse (relapse within 12 months since diagnosis or the end of first-line treatment, ER) or primary refractory had an even worse prognosis. Thus, the investiga
| Condition(s) | Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | As the most common subtype of lymphoma, diffuse large B-cell lymphoma (DLBCL) is an aggressive but potentially curable malignancy. However, patients with early relapse (relapse within 12 months since diagnosis or the end of first-line treatment, ER) or primary refractory had an even worse prognosis. Thus, the investigators plan to evaluate the efficacy and safety of anlotinib combined with rituximab, gemcitabine, oxaliplatin (A-RGEMOX) in the treatment of early relapsed/refractory diffuse large B-cell lymphoma. |
| Who can participate | Inclusion Criteria: * Participate in the clinical study voluntarily: fully understand and be informed of the study and sign the informed consent in person; Willing to follow and be able to complete all test procedures. * Age≥18 years old, ECOG score ≥2 points, both male and female. * Histopathologically confirmed as diffuse large B-cell lymphoma, not otherwise specified; high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement; high-grade B-cell lymphoma, not otherwise specified; EBV positive diffuse large B-cell lymphoma * Must meet one of the following conditions: 1. Early relapse: response (≥PR) to first-line systemic therapy (including rituximab and anthracyclines) and disease progression within 12 months after the end of treatment; 2. Refractory: first-line treatment inc |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Zhejiang Cancer Hospital |
| Locations | Hangzhou, Zhejiang, China |
| Start date | 2023-10-01 |
| NCT ID | NCT06086197 |
| Official listing | https://clinicaltrials.gov/study/NCT06086197 |